Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
November 8, 2017 7:00 AM EST260+ Fabry Patients on Reimbursed Galafold (Migalastat) and On Target to Reach 300 Patients by Year-End 2017
U.S. NDA Submission for Migalastat Planned in 4Q17
Pompe Retrospective and Prospective Data Collection Studies Initiated
Additional Pompe Clinical Data to be Presented at WORLDSymposium in February 2018
CRANBURY, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of... More
